Aurinia Establishes At-The-Market Facility
November 09 2016 - 4:05PM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia”
or the “Company”) today announced that it has entered into a
Controlled Equity Offering Sales Agreement with Cantor Fitzgerald
& Co. (“Cantor”) pursuant to which the Company may from time to
time sell, through at-the-market (“ATM”) offerings with Cantor
acting as sales agent, such common shares as would have an
aggregate offer price of up to US$8,000,000. Aurinia has also filed
a prospectus supplement with securities regulatory authorities in
Canada in the provinces of British Columbia, Alberta and Ontario,
and with the United States Securities and Exchange Commission,
which supplements Aurinia’s short form base shelf prospectus dated
October 16, 2015, and Aurinia’s shelf registration statement on
Form F-10 dated October 16, 2015, declared effective on November 5,
2015. The listing of any shares sold pursuant to the ATM offering
is subject to the approval of the Toronto Stock Exchange and
NASDAQ. Cantor, at Aurinia’s discretion and instruction, will use
its commercially reasonable efforts to sell the common shares at
market prices from time to time. Sales in the ATM Offering will
only be conducted in the United States through NASDAQ or another
exchange at market prices. No sales will be conducted in Canada or
through the Toronto Stock Exchange.
Aurinia currently intends to use the proceeds from sales related
to the ATM offering, if any, primarily to fund its lupus nephritis
(“LN”) clinical trial program for voclosporin, including costs
associated with initiating its planned Phase 3 clinical trial and
for working capital and general corporate purposes. This press
release shall not constitute an offer to sell or a solicitation of
an offer to buy, nor shall there be any sale of these securities in
any jurisdiction in which an offer, solicitation or sale would be
unlawful prior to registration or qualifications under the
securities laws of any such jurisdiction.
Copies of the prospectus supplement and the accompanying
prospectus relating to these securities may be obtained by
contacting Cantor Fitzgerald & Co., Attention: Equity Capital
Markets, 110 East 59th Street, New York, New York 10022, telephone:
212-829-7122.
About Aurinia
Aurinia is a clinical stage biopharmaceutical company focused on
developing and commercializing therapies to treat targeted patient
populations that are suffering from serious diseases with a high
unmet medical need. The company is currently developing
voclosporin, an investigational drug, for the treatment of lupus
nephritis (LN). The company is headquartered in Victoria, BC.
Canada and focuses its development efforts globally.
Cautionary Note Regarding Forward-looking Statements
This press release contains forward-looking statements.
Forward-looking statements in this news release include statements
about the possible sales of common shares and statements of the
current intended use of proceeds from the sale of shares, if any.
The forward-looking statements may include, without limitation,
statements that the net proceeds from the sale of the common shares
will be used primarily to fund its LN clinical trial program for
voclosporin, including costs associated with initiating its planned
Phase 3 clinical trial, and for working capital and general
corporate purposes. Such forward-looking statements involve known
and unknown risks, uncertainties and other factors that may cause
actual results, events or developments to be materially different
from any future results, events or developments expressed or
implied by such forward looking statements. Such risks and
uncertainties include, among others, the ability of the Company to
protect its intellectual property rights, securing and maintaining
corporate alliances and partnerships, the need to raise additional
capital and the effect of capital market conditions and other
factors on capital availability, the potential of its products, the
success and timely completion of clinical studies and trials, and
the combined company's and its partners' ability to successfully
obtain regulatory approvals and commercialize voclosporin on a
timely basis. These factors should be considered carefully and
readers are cautioned not to place undue reliance on such
forward-looking statements. For additional information on risks and
uncertainties relating to these forward-looking statements,
investors should review the prospectus supplement and accompanying
prospectus and consult the Company's ongoing quarterly filings,
annual reports and the Annual Information Form and other filings
found on SEDAR at www.sedar.com and on EDGAR at
www.sec.gov/edgar.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161109006333/en/
Aurinia Pharmaceuticals Inc.Investor & Media
Contact:Celia EconomidesHead of IR &
Communicationsceconomides@auriniapharma.com